Patient Guide: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 56 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05319730
Status: 🟢 Enrolling Now
Condition: Esophageal Squamous Cell Carcinoma
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 56 locations across the country.

Top locations include:
  • • Tucson, Arizona
  • • Los Angeles, California
  • • East Syracuse, New York
  • • And 53 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) - Join Clinical Trial NCTNCT05319730

How to Join This Clinical Trial - NCTNCT05319730

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Esophageal Squamous Cell Carcinoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Esophageal Squamous Cell Carcinoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Esophageal Squamous Cell Carcinoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05319730 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 56 locations. Find a study site near you:

Clinical Research Site

Tucson, Arizona 85719 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90404 - United States

Status: RECRUITING

Clinical Research Site

East Syracuse, New York 13057 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10032 - United States

Status: COMPLETED

Clinical Research Site

Pittsburgh, Pennsylvania 15232 - United States

Status: RECRUITING

Clinical Research Site

Natal, Rio Grande do Norte 59062-000 - Brazil

Status: RECRUITING

Clinical Research Site

Porto Alegre, Rio Grande do Sul 91350-200 - Brazil

Status: RECRUITING

Clinical Research Site

São Paulo, 01246-000 - Brazil

Status: RECRUITING

Clinical Research Site

Santiago, Region M. de Santiago 7500921 - Chile

Status: RECRUITING

Clinical Research Site

Santiago, Region M. de Santiago 7560908 - Chile

Status: RECRUITING

And 46 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Esophageal Squamous Cell Carcinoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships